BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths.
Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.
CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring mitochondrial-derived peptides within the mitochondrial genome that regulate metabolism and cell death, and whose biological activity declines with age. To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs. CohBar’s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, fibrotic diseases, cancer, acute respiratory distress syndrome (ARDS), type 2 diabetes, and cardiovascular and neurodegenerative diseases. The company’s lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity. This clinical trial is currently paused due to the COVID-19 pandemic. In addition, CohBar has four preclinical programs, two in cancer, one in fibrotic diseases and one in COVID-19 associated ARDS and type 2 diabetes.
ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival from 10% upto 50% in critically ill patients on intensive care. The ADVOS treatment in severely ill COVID-19 patients with MOF achieve similar results. Each year, 60% of intensive care patients - 500,000 individuals in Western Europe and the US - die of MOF. The coronavirus outbreak will further increase this number dramatically as COVID-19 often leads to MOF. The innovative ADVOS therapy has the potential to revolutionize intensive care therapy of patients worldwide, as it is the 1st and only blood purification therapy combining liver, lung, kidney support and direct blood pH correction in 1 device (technology leader in removal of liver toxins and fast extracorporeal blood pH correction). It will help to save lives in the current Corona crisis. The ADVOS therapy is low-invasive as standard hemodialysis, so it can support by far more ICU patients than other devices (that have a higher risk profile). The ADVOS device has the CE mark; the business model is validated in Germany with 40 installed devices (20 customers) and first revenues (2019: 2m€).
Allelica is the genomic software company that developed the first Software as a Service (SaaS) to perform prediction analysis of complex diseases using genomics and clinical data. The SaaS is used by clinical genetics lab and pharma companies. Allelica is using its technology to identify people who will develop the highest severity of COVID-19 clinical manifestation. This product has immediate clinical utility in the health care setting by improving disease outcome and will play a pivotal role during the first round of vaccination.
Amniotics™ has developed a unique pipeline of cell therapeutics combining the desirable properties of neonatal source and tissue specificity. Our product is therefore tailored to the organ of choice (such as e.g. lung, kidney, or CNS/brain) or any combination thereof. The feature of our technology combines the potency, proliferative capacity, and differentiation capability of neonatal cells with tissue-relevance, making it possible to treat corresponding tissues. This makes our pipeline ideally suited for therapies in which there is a need for organ-specific repair, with an elevated chance of success in treatment.
London-based AquAffirm develops innovative mapping, tracking and prediction software which has been redeployed to address the novel coronavirus crisis. We are developing the COVID-EXIT digital platform, an advanced subscription-based digital platform, to help government healthcare-providers and multi-national companies safely manage the COVID-19 crisis. Our platform will provide a web-based tool incorporating sophisticated epidemiological prediction algorithms to help governments model various restriction / intervention scenarios while helping companies plan for the safe re-opening of the economy. Our business model is based on tiered subscriptions to the COVID-EXIT PRO website, with large-company users paying a monthly subscription fee. We further anticipate other companies contracting us to develop customised interactive user interfaces for their specific needs. Our strong link with one of the world’s leading academic epidemiology groups has already attracted interest from a plethora of private groups around the world, while our COVIDSIM.ORG website continues to attract thousands of users a day.
BioXplor is launching an open-access COVID-19 R&D Platform for rapid literature-based knowledge discovery and AI / data-driven drug discovery solutions. The COVID-19 literature-based discovery engine can be rapidly queried with up to 25x faster actionable insights in over 20 biomedical categories, from ~7 million structured sentences in 29k+ COVID-19 scientific papers plus another ~1 billion structured sentences in the drug discovery engine. COVID-19 solutions include drug repositioning, patient responder identification, safety & toxicity, drug resistance, target prioritization, pathway analysis, sequencing primer/antibody assay design. Scientists, patients, and life science vendors can upload COVID-19 scientific and medical documents.
BookingClinic is the first integrated smart online platform, that connects Patients to Doctors and Clinics. It offers virtual medical consultation via videocall and online booking of treatments, fostering quality and accessibility in patient’s choice.
BookingClinic.com aims to serve the patients who need to consult a doctor and/or have a treatment. It offers a friendly, trustful online tool to virtually meet a Doctor (via videocall), receive trustworthy medical consultation and finally Find, Compare and Book the best Clinic with the Doctor of choice at the Best Price. Patients have a 24/7 access to transparent info and data on medical experience, hospitality info, customer satisfaction ratings and total costs for more informed decisions . Online videocall is offered, upgrading customer’s experience and trust. Clinics can promote their services, use a new digital channel to attract patients from new markets and improve their services by receiving feedback from patients. The can enter the Health e-market by offering new digital services, upgrading patients’ experience.
Byteflies is an ISO13485 (medtech) company that provides B2B-services to enable lean development of wearable health applications. We envision a future where healthcare is truly personalized, predictive, preventive, and participatory. Wearable technologies that enable 24/7 acquisition of accurate and synchronized vital signs and clinically-validated digital biomarkers are a crucial facilitator of this transition. With a proprietary platform to set up wearable health solutions instantly, Byteflies works with researchers looking for cutting edge technology to monitor patients and pharmaceutical companies that are embracing clinical trial innovation and the value-based healthcare model.
Check Your Health is a B2C ecommerce company that offers fast, accurate and confidential at-home lab testing kits and digital results within days. Check Your Health connects consumers to lab partners and offers complete & understandable check-up's such as thyroid, fertility, STIs or COVID Screening (PCR and Antibody). https://www.checkyourhealth.ch/
Climedo Health GmbH
Climedo’s mission is to bring the best treatment to every patient by empowering healthcare professionals with intelligent software solutions. Our cloud-based platform enables cutting-edge clinical validation and product surveillance of medical devices and pharmaceutical products. By connecting all stakeholders (medical device manufacturers, pharma companies, CROs, hospitals), we allow for increased performance, better cost-efficiencies - and ultimately - accelerated medical innovation.
Corti - Audio-based AI assistant for patients and healthcare professionals
Corti.ai is a European company based in Copenhagen, Denmark, that develops state-of-the-art artificial intelligence software to analyze patients' interviews, and guide healthcare professionals, in order to reduce over- and under-triage. Corti has built a technology that uses machine learning to analyze patients’ symptoms by listening to a large number of historic interviews. The goal is to gain a deeper understanding of what is being said and shared, in order to help the nurse, dispatcher, or doctor triage or diagnose the patient.
Our solutions stimulate innovation in the European healthcare industry by exploring advanced technologies, improving the working conditions of healthcare professionals, and promoting regulatory science. New opportunities will be opened for substantially improving the quality of services provided by healthcare workers through the utilization of AI.
Corti currently employs a multidisciplinary team of experts in the fields of machine learning, software architecture and design, software development, business development, and marketing. Staff members have previous experience from organizations such as Apple, NASA, Imperial College London, and IBM Watson.
We have been recognized for our achievements by over 100 international media outlets and our product has won numerous awards, including the 2020 Future Unicorn Award, which highlighted our potential to become a European tech giant.
We founded DBS System to simplify and reduce the cost of blood sampling by replacing the blood tube, nurse, collection center, cold storage, and centrifuge with reliable and easy to use devices based on microfluidic technology. We are on a mission to democratize blood sampling and improve lives globally.
We have developed, patented, industrialized and certified our blood collection device, called HemaXis. It is in the market and generating revenue with a number of growing customers in Europe.
It allows for easy, safe, fast and reliable blood sampling anywhere and at anytime. With HemaXis, it is the sample that travels, not the patient.
Documental Ltd is company involving multisectoral experts and developing digital solutions for mental health and was established in November 2016. The DocuMental contributes to more precise and personalised mental healthcare through the integration of IT innovations, digital phenotyping, genetic approaches and cloud-based facilities and technologies in order to improve the management of mental disorders.
Drivesec srl is a cybersecurity company whose main scope is to develop products and solution to secure connected system in the automotive and Internet of Things (IoT) domains. In the economy of convenience everything must be connected and ease at use and personalized experience are requested by the customer all the time. In this Scenario cyber protection is a “must to have” components in order to enable safe and durable systems and business model.
Drivesec has been founded in 2017 with the aim to support Companies developing products in automotive and IoT to define they security target and improve the design of their systems. https://www.drivesec.com/
Epcon integrates Spatial Technologies (GIS), Health and Data Science (AI) to create the Epidemic Control Platform (ECP).
To enable this and generate value we use a powerful machine learning engine that adds an intelligence component to augment reference data and variables. Our models identify cause-effect patterns in complex datasets spanning multiple variables. We generate a digital representation of the health program (twin model) and quantify risks at the population and the individual level. Data and learnings get visualised and inference queries can be executed on observed variables from relationships between historical and present data.
Given contextual information and routine disease data generated from a region, the platform will dynamically quantify risks for COVID transmission, produce program insights, provide recommendations and actionable output that enables more effective and tailored interventions at the local level.
Our engine is disease agnostic and has been initially implemented for the identification of TB hotspots and finding missing cases in Africa and the Middle East. At present we are implementing a COVID model in Europe (Belgium).
Eversens provides a complete hardware and software solution that includes four portable devices based on Exhaled Nitric Oxide Measurement (eNO), as an important biomarker of airway inflammation, and a powerful e-platform that connects them, offering a holistic approach for asthma management. http://www.eversens.com/
Healex solutions accelerate and improve clinical research and trial management for SARS-CoV-2 and Covid-19-research.
Healex bridges the gap between Clinical Research and Healthcare by bringing clinical data to the right place at the right time.
Our Healex Site Management System and Clinical Documentation System speeds up the management of clinical data at every step - from planning a clinical trial to study execution resulting in personalized patient therapies. Many leading university hospitals and research organisations are using the Healex SMS in multi-site studies on SARS-CoV-2 and Covid-19, als well as in capturing and utilising patient data by Covid-19 patients in clinical research.
Healex provides software infrastructure for rapid integration of high-quality structured data at every stage, in real time and across multiple sites thus facilitating the move to a FHIR based healthcare industry. Our FHIR platforms enables the integration of live clinical data in clinical trials and therapies.
Our Corona web tools provide high quality structured clinical data for Covid-19 research and enable enable quick transmission of test results, symptom recording and safe visitor management at hospitals and other places.
Healex software is proven by over 6300 researchers at 340 hospitals and across 3000+ studies.
IDOVEN is a pioneer eHealth startup that is redefining the way cardiac arrhythmias are diagnosed in citizens, athletes and patients using artificial intelligence algorithms.
IDOVEN analyses cardiac electrical activity from electrocardiograms of any duration (up to 85 days so far) and transform the patterns extracted from millions of heart beats into clinically relevant information.
We believe that early diagnosis of cardiac diseases, based on artificial intelligence and combined with real-life studies, will transform clinical practice by reducing heart diseases and sudden arrhythmic events in a personalized way.
ImmunoLogik GmbH is developing the active ingredient IML-206 as a broadly acting antiviral drug for the therapy of patients with a SARS-CoV-2 induced COVID-19 infection or other coronavirus patients and the active ingredient IML-106 for the treatment of HIV-1 infected patients who exploited all available means of the modern therapy, and who would die on AIDS.
InterK Peptide Therapeutics is a pre-clinical biopharmaceutical company located in Sydney, Australia focussed on developing a proprietary immune-boosting platform for treatment and immunisation strategies.
The Company’s technology platform includes a peptide that has the potential to reduce Covid-19 infection and associated lung inflammation by modulating selected signalling pathways within infected cells. This same compound may also act as an adjuvant to boost the response of the immune system upon vaccination against this virus.
Hence, InterK’s ground-breaking technology serves to stimulate signalling pathways in immune cells that augment the innate and adaptive immune responses needed in combating coronaviruses.
Intrepida is a health tech that has built Ancora.ai to support the surge of new COVID-19 clinical trials with recruitment. Ancora.ai is an AI-powered online platform that helps patients and healthy volunteers search for, match with and connect to clinical trials for the treatments, diagnostics and vaccines that will help to stop the Coronavirus pandemic. Even in non-pandemic conditions, clinical trials are a 44B USD industry that is broken and not designed for patients. Our vision is to make trials more accessible, which will help to diversify trials, bring treatments to market faster, and reduce challenges for sponsors. We tackle this problem with a uniquely qualified team that understands both patient and sponsor challenges.
Co-founded by a former nurse, libheros is the first "phygital" solution to accompany patients, family caregivers and hospitals in the organization, coordination and follow-up of healthcare at home (nurse cares, medical equipment, caregivers, ...), thanks to our community of more than 12,000+ healthcare professionals exercising at home, our in-house coordinators / care managers and our digital tools and technology. libheros is even more powerfull for patient and hospitals in the current Covid crisis we are facing, by helping Covid patients to e.g. follow their symptoms, through teleconsultation, our community of nurses, but also for non-Covid patients that have a chronical disease to continue their treatment and to be accompany by experts
Longenesis has been changing the R&D industry with an end-to-end environment for data aggregators, including doctors and clinical investigators, and research collaboration partners and sponsors. It enables safe data showcasing and compliant, consent-enabled clinical data utilization for research.
Currently, Longenesis is having pilot case studies on Breast Cancer digital prescreening, as well as deployments for National Genome initiative in the Middle East and Northern Europe and APAC region. Longenesis has been selected to take part in the annual EIT Health Headstart program and is an Amazon APN member and received a finalist nomination prize at MedTech Innovator APAC Region 2019.
Mymetics is a Swiss based biotechnology company, with a Research Lab in the Netherlands focused on development of vaccines based on our proprietary virosome platform. Our vaccines are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Our unique approach has resulted in the development of a rich pipeline of vaccine candidates for HIV-1/AIDS, intra nasal Influenza, Malaria, Chikungunya and the Respiratory Syncytial Virus (RSV) vaccine. Recently we have expanded our development field into immunotherapy for cancer and allergies. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations. The company is registered in the US and trades on the OTCQB, venture stage market place – fully SEC compliant.
Netsensing Technology Sàrl is a Swiss medtech startup, founded in 2017 which has patented a methodology to enable the mass detection of sleep apnea. This methodology is fully compliant with the American Academy of Sleep Medicine.
Neurix is a biotech CRO based in Geneva. We help pharmaceutical companies choosing the right drug to be tested in clinic, by providing custom cell- and organoid-based assays for the preclinical testing of drug compounds.
We want to help finding a potent treatment against the devastating SARS-CoV-2 pandemic, and develop cell-based assays:
- For the diagnosis of patient by measuring functional plasma antibodies - For the identification of inhibitors of viral entry or RNA polymerase - For the measurement of custom inflammation markers or genes related to SARS-CoV-2 https://www.neurix.ch/
Pleaz is a digital platform with science-based active breaks for your workday. WHO has identified sedentary behavior as the world’s 4th leading risk factor for mortality and morbidity.
Pleaz is deeply committed to address the serious health issue of sedentary lifestyles. We help organizational members become more physically active through active breaks during the workday. All our active breaks are designed to increase physical health and promote mental and social well-being in a fun and effective way. We provide simple and short video instructions for every work situation to lower the barrier for engaging in physical activity during work hours. Every active break is supported by a scientific reason, stating exactly what the benefits are for each employee.
The platform was created in an innovation partnership with Nestlé Nordic and their strong employee health program which we have signed a 12 months POC with. The results from Q1-Q2 have been so successful that we are now negotiating the terms of a global expansion for 300.000 Nestlé employees worldwide.
Preci Health is offering a true first-in-class breakthrough for the rapidly expanding pre-filled auto-injectors and blood sampling market.
Preci Health puts the best of Swiss technology in micro-mechanics and micro-fluidics to increase the autonomy, comfort and safety of the patients, while submitting to the constraints of the biotech and pharma industries, without increasing costs.
Proteona Antibody Protection GmbH (PAP) is a biomedical company operating at the forefront of the fight against COVID-19 using single cell sequencing technology to discover neutralizing antibodies. Proteona’s vision is to accelerate treatment development for the most vulnerable, immunocompromised patients.
We do this by utilizing our own single cell technologies to identify the best candidate antibodies and then moving those antibodies through functional testing toward the clinic by tapping on the individual strengths of a team of the top international companies and research institutes in the world who have agreed to form an alliance for the purpose of fighting COVID-19.
Proteona Antibody Protection GmbH was established in 2020 in response to the dire need of immunocompromised individuals, such as those with blood cancer, for a targeted treatment against COVID-19. Its parent company, Proteona, is already active in Singapore and Germany, where it provides single-cell multi-omics data for researchers, clinicians and pharma companies for drug discovery and for treatment optimization for blood cancer patients.
RAMPmedical is an evidence and AI based therapy decision support tool that helps doctors to find the best therapy for each patient. It provides doctors with a software solution that supports them in identifying the optimal treatment for each of their patients and avoiding treatment mistakes for diabetes type 2, arterial hypertension, and bacterial community-acquired pneumonia.
RAMPmedical aggregates data from medical guidelines, product characteristics, and clinical trials, adapting all this knowledge to patient specificities and showing all relevant parameters for a therapy decision. Those parameters include, among others, on-label and off-label efficacy, safety, contraindications, interactions, mechanisms of action, prices.
RedHill Biopharma is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases. RedHill has commercial operations in the U.S., with a sales force promoting several gastrointestinal drugs across the U.S., including RedHill’s recently FDA approved drug, Talicia® for H. pylori infection. RedHill also has a robust development pipeline with several clinical late-stage development programs which have successfully completed Phase 2 and Phase 3 studies. Near-term milestones include a planned pivotal Phase 3 study for pulmonary NTM infections and an ongoing Phase 2/3 development program for COVID-19 and Phase 2 programs in oncology indications.
ResonanceDx is an emerging point of care diagnostics company that has a unique resonance frequency-based platform for quick identification of a wide range of proteins. Our first product is focused on quick (>5 mins) diagnostic testing of Covid-19 in the doctor’s office, airport, stadium entrance, school yard, or office building allows the physician to quickly triage and treat and allows businesses, schools, and entertainment facilities to safely operate. The diagnostic test is based on a disposable USB card that contains a cavity resonator which can have up to 27 different targeted antibody-antigen markers bound on the surface. When a patient’s sample has the targeted antigen(s), they bind to the antibody on the resonator and the frequency shift is detected. To date the company has t and shown detection of SARS-CoVid-2 virus and MYH9 (positive control saliva protein), as well as p16, AKT, and γH2AX and classification of HPV positive and HPV negative head and neck cancer cell lines the results of which were published in Sensors and Actuators B-Chemical 190, 165-170 (2014). The platform can be used for the unmet market need to quickly diagnose infectious organisms, cancers, and progressive disease diagnosis. The company founders have combined over 55 years of experience developing and commercializing new healthcare technology, 70 years in cancer research, and over 30 years in the research and development of medical device technologies. The company is focused on successfully developing, obtaining regulatory clearance for, and commercializing a point of care platform that can be used to rapidly detect a wide range of targeted biomolecules from multiple source types (serum, urine, saliva, cerebral spinal fluid, etc.) to help reduce patient morbidity/mortality as well as reducing healthcare costs.
ScintHealth’s self-disinfecting rooms are a complete solution for safe and fast disinfection of surfaces and the air in hospital rooms, as well as medical practices and ambulances. The solution consists of smart ultraviolet C (UVC) systems that have the means for being aware of humans, such that they can disinfect rooms whenever needed while avoiding harm. Next to its products’, ScintHealth offers a service for testing and simulating the needed system configurations and irradiation times to guarantee the disinfection of surfaces for different germs including SARS-CoV-2, the virus causing CoViD-19. Next to its UVC technology, ScintHealth is active in the development of radiation therapies for multiple cancer types.
Serenmind is a mobile app offering self-guided psychological programs, based on cognitive-behavioral techniques that have proven effective. It consists of a psychoeducational part with audios, tools to practice and Serena, a virtual therapist that accompanies the user during the whole process. We aim to make psychology accessible to everyone.
Upstream Health is on a social mission to support the shift needed to upstream preventative care delivery. We bring technology innovation to healthcare delivery using Artificial Intelligence, combined with mobile and analytics platforms, to improve access to technology and health outcomes. Upstream receives extensive support from Microsoft as part of their first Global #AIforgood cohort.
We are revenue making and for our new product, Bridgit helping the elderly to stay well and for long in their own homes. We have an NHS England trial underway, and are keen to grow our business outside the UK. Upstream will shortly be named by the UK Department of International trade on their Top 100 digital health businesses for UK export.
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.
VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor and it can be readily adapted to target a wide range of cancer-related antigens. With VAXIMM’s highly adaptable platform, a COVID-19 vaccine development project has recently been initiated.
The Vaccine Formulation Institute (VFI) is a not-for-profit company based in Geneva and Lausanne, Switzerland. VFI is dedicated to provide novel adjuvant and vaccine formulation technologies in open-access to vaccine developers worldwide.
WAMA Diagnostics (Switzerland) was established by a larger group of companies, which includes WAMA Diagnóstica located São Paulo state from Brazil. The later was founded in 1991 and develops, manufactures and sells In Vitro Diagnostics products for South America market through its net of 45 distributors in Brazil and its representatives from other South American countries. WAMA Switzerland was created with the goal to mainly develop innovative IVD assays and later on to explore European IVD market. Since its establishment, the Swiss company is working on the development of multiplex assays to screen different infectious diseases. These assays and their users will benefit from the advantage of such platform, which makes time to result faster and less costly. The company proposes to use the accumulated knowledge to develop a multiplex assay that integrates, on a single reaction, the identification of three classes of antibodies IgA, IgM , and IgG specific to SARS-CoV-2.